JOP20210126A1 - طرق علاج سرطان الغدد الليمفاوية الجريبي - Google Patents

طرق علاج سرطان الغدد الليمفاوية الجريبي

Info

Publication number
JOP20210126A1
JOP20210126A1 JOP/2021/0126A JOP20210126A JOP20210126A1 JO P20210126 A1 JOP20210126 A1 JO P20210126A1 JO P20210126 A JOP20210126 A JO P20210126A JO P20210126 A1 JOP20210126 A1 JO P20210126A1
Authority
JO
Jordan
Prior art keywords
follicular lymphoma
treatment methods
treatment
ibrutinib
predict
Prior art date
Application number
JOP/2021/0126A
Other languages
Arabic (ar)
English (en)
Inventor
Sriram Balasubramanian
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of JOP20210126A1 publication Critical patent/JOP20210126A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JOP/2021/0126A 2018-11-30 2019-11-26 طرق علاج سرطان الغدد الليمفاوية الجريبي JOP20210126A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773678P 2018-11-30 2018-11-30
PCT/US2019/063234 WO2020112761A1 (en) 2018-11-30 2019-11-26 Methods of treating follicular lymphoma

Publications (1)

Publication Number Publication Date
JOP20210126A1 true JOP20210126A1 (ar) 2019-11-26

Family

ID=68966021

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0126A JOP20210126A1 (ar) 2018-11-30 2019-11-26 طرق علاج سرطان الغدد الليمفاوية الجريبي

Country Status (16)

Country Link
US (1) US20200171034A1 (https=)
EP (1) EP3886992A1 (https=)
JP (1) JP2022513666A (https=)
KR (1) KR20210097160A (https=)
CN (1) CN113164782A (https=)
AU (1) AU2019388899A1 (https=)
BR (1) BR112021009978A2 (https=)
CA (1) CA3120960A1 (https=)
EA (1) EA202191509A1 (https=)
IL (1) IL283365A (https=)
JO (1) JOP20210126A1 (https=)
MA (1) MA54292A (https=)
MX (1) MX2021006368A (https=)
PH (1) PH12021551140A1 (https=)
SG (1) SG11202105309YA (https=)
WO (1) WO2020112761A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2983670A4 (en) * 2013-04-08 2017-03-08 Pharmacyclics LLC Ibrutinib combination therapy
CA2914284A1 (en) * 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US20160032404A1 (en) * 2014-08-01 2016-02-04 Pharmacyclics Llc Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
CA2980393A1 (en) * 2015-03-18 2016-09-22 Memorial Sloan Kettering Cancer Center Methods for diagnosing and treating follicular lymphoma
HK1250925A1 (zh) * 2015-04-06 2019-01-18 Janssen Pharmaceutica, N.V. 包含依鲁替尼的组合物
WO2017087947A2 (en) * 2015-11-19 2017-05-26 Pharmacyclics Llc Method of treatment of follicular lymphoma with a btk inhibitor
PH12021551936A1 (en) * 2019-02-15 2022-05-23 Janssen Biotech Inc Combination therapy for treatment of b-cell malignancies

Also Published As

Publication number Publication date
CN113164782A (zh) 2021-07-23
SG11202105309YA (en) 2021-06-29
KR20210097160A (ko) 2021-08-06
EP3886992A1 (en) 2021-10-06
US20200171034A1 (en) 2020-06-04
JP2022513666A (ja) 2022-02-09
EA202191509A1 (ru) 2021-10-26
BR112021009978A2 (pt) 2021-08-17
WO2020112761A1 (en) 2020-06-04
MA54292A (fr) 2021-10-06
PH12021551140A1 (en) 2021-10-25
AU2019388899A1 (en) 2021-06-10
IL283365A (en) 2021-07-29
MX2021006368A (es) 2021-10-13
CA3120960A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
PH12021551439A1 (en) Irreversible inhibitors of menin-mll interaction
PH12021550152A1 (en) Anti-cd112r compositions and methods
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
MY196631A (en) Antibody Agents Specific for Human Cd19 and uses Thereof
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
EA201891607A1 (ru) Axl-специфичные конъюгаты антитело-лекарственное средство для лечения злокачественных новообразований
EP4302782A3 (en) Napi2b-targeted antibody-drug conjugates and methods of use thereof
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
MA38827A1 (fr) Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives
EP4286013A3 (en) Lrrc33 inhibitors and use thereof
MY179105A (en) Methods of treating alzheimer's disease
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
MX2020011817A (es) Metodos para tratar el linfoma.
WO2019175260A3 (en) Modified oligonucleotides for use in treatment of tauopathies
MX2018014432A (es) Materiales y metodos relacionados con el diseño del regimen de dosificacion.
MX2017013047A (es) Tratamiento de dolor.
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
JOP20210126A1 (ar) طرق علاج سرطان الغدد الليمفاوية الجريبي
AR112531A1 (es) Tratamiento de cáncer usando una cepa de blautia
DK2155179T3 (da) Axomadol til smertebehandling arthrose
TW201613926A (en) Inhibitors of bruton's tyrosine kinase